Physician profile
Robert A Black
NPI 1508826785
$129,030.84
in general payments reported to CMS, 2019-2025
36 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $4,140 · 2021: $8,013 · 2022: $18K · 2023: $7,962 · 2024: $22K · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $3,739 · Long Term Medical Supply Or Device Loan: $3,500 · Travel and Lodging: $195 · Gift: $50.00 · Education: $3.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,796.00 |
| Food and Beverage | $3,738.71 |
| Long Term Medical Supply Or Device Loan | $3,500.00 |
| Travel and Lodging | $194.63 |
| Gift | $50.00 |
| Education | $3.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $120,346.79 | 2019-2024 | Xarelto |
| Exo Imaging, INC. | $3,550.00 | 2024 | Exo Iris |
| Novartis Pharmaceuticals Corporation | $650.82 | 2019-2025 | |
| Amgen INC. | $572.55 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $539.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $434.08 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $426.39 | 2022-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $413.97 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.53 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $152.76 | 2024-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $138.78 | 2019-2023 | |
| Amarin Pharma, INC. | $117.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $114.03 | 2021-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $109.50 | 2019-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $102.53 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.